Both institutions have renewed the agreement signed in 2019 to finance until December 2020 the project "Detection and characterization of autoantibodies against perilipin 1 in patients with generalized acquired lipodystrophy (Lawrence syndrome)". This research is led by Pilar Nozal Aranda, researcher at the Consortium for Biomedical Research on Rare Diseases M.P. Network (CIBERER) and the Hospital La Paz in Madrid, and Santiago Rodríguez de Córdoba, from CIBERER and the Centro de Investigaciones Biológicas (CSIC).
This research project aims to analyse the presence of antibodies against perilipin 1 protein in a cohort of patients with acquired generalised lipodystrophy. Previous studies by the group have described for the first time the existence of these autoantibodies and their relationship with the lipodistrophic phenotype in patients. To this end, AELIP will donate 17,687 euros, which will be used entirely for the development of this project. The amount donated will be made in two payments of 50% of the amount, the first in July and the second in November.
In addition, the aim is to test blocking peptides to restore the harmful effect of these autoantibodies in a model of human pre-adipocytes in culture, which gives the project a translational purpose. The study will also extend the research objectives to study patients with partially acquired lipodystrophy (BarraquerSimons syndrome) in the same terms
